• Molecular NameEncainide
  • SynonymEncainida [Spanish]; Encainide [French]; Encainidum [Latin]
  • Weight352.478
  • Drugbank_IDDB01228
  • ACS_NO66778-36-7
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)4.09
  • pka10.2
  • LogD (pH=7, predicted)1.63
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-2.02
  • LogSw (predicted, AB/LogsW2.0)0.08
  • Sw (mg/ml) (predicted, ACD/Labs)0.02
  • No.of HBond Donors1
  • No.of HBond Acceptors4
  • No.of Rotatable Bonds6
  • TPSA41.57
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA class Ic antiarrhythmic agent.
  • Absorption_valueN/A
  • Absorption (description)Encainide is well absorbed
  • Caco_2N/A
  • Bioavailability27.0
  • Protein binding74.0
  • Volume of distribution (VD)265 L
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmExtensively metabolised in the liver to two active metabolites, (ODE) and (MODE). Inactive metabolites include (NDE) and sulfate and glucuronide conjugates. The extent of metabolism varies between individuals as there are extensive metabolisers and poor metabolisers.
  • Half lifeFor encainide, 2.5 h (extensive metabolisers) and 8 to 11 h (poor metabolisers). For ODE, 4 to 8 h and MODE, 12 to 20 h.
  • ExcretionApprox. 7% of the Caucasian and Black population are poor metabolisers. Excretion varies between these individuals but is mainly via urine with approx. 30% of a dose present in faeces. 39% of an administered dose is found in the urine of poor metabolisers but only 4.9% for extensive metabolisers with 10.6% ODE and 3.6% MODE.
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicitySevere and potentially fatal ventricular tachycardia and cardiac arrest, congestive heart failure and seizures. Toxicity observed with ODE concentrations > 300 μg/L.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A